Roche signs $15 billion ADC partnership with China's Hansoh, offering $400 million upfront

Roche announced a licensing agreement with Hansoh Pharmaceutical to develop a broad portfolio of antibody-drug conjugates (ADCs).\n\nThe deal includes an upfront cash payment of $400 million and a $110 million payment after one year, with the potential total value exceeding $15 billion through milestones and royalties.\n\nHansoh will handle development through global Phase 1a trials, while Roche will take responsibility for later stages outside mainland China, Hong Kong, Macau and Taiwan.\n\nThe collaboration builds on a previous ADC alliance and gives Hansoh the option to contribute to non-Asian development for two programs and earn additional revenue from U.S. markets.